SCN8A-Related Epilepsy

SCN8A-related epilepsy is part of a broad neurodevelopmental spectrum caused by pathogenic variants in SCN8A, which encodes the Nav1.6 neuronal sodium channel. Phenotypes range from self-limited infantile epilepsy to severe developmental and epileptic encephalopathy, and some people have neurodevelopmental disability without epilepsy.

A spectrum rather than one syndrome

Recognised SCN8A phenotypes include severe DEE, mild-to-moderate DEE, self-limited familial infantile epilepsy, neurodevelopmental disorder with generalised epilepsy and neurodevelopmental disorder without epilepsy.

This wide range reflects different molecular effects of different variants.

Gain-of-function variants

Many focal-epilepsy and DEE phenotypes are associated with gain-of-function variants that increase Nav1.6 activity.

Seizures often begin in infancy and can be frequent and drug resistant.

Loss-of-function variants

Loss-of-function variants are more often associated with developmental disorders with generalised epilepsy or developmental disability without epilepsy.

This distinction has direct treatment relevance.

Seizure types

Seizure types can include focal seizures, multifocal seizures, bilateral tonic-clonic seizures, tonic seizures and epileptic spasms.

Generalised absence or tonic-clonic seizures can occur in loss-of-function phenotypes.

Age at onset

Severe SCN8A-DEE commonly begins within the first months of life.

Self-limited infantile epilepsy usually begins later in infancy and has a much more favourable developmental course.

Development

Severe DEE is often associated with moderate-to-profound developmental impairment, hypotonia and limited speech or mobility.

Milder phenotypes can have normal or only mildly delayed development.

EEG and MRI

EEG can show focal, multifocal or generalised abnormalities depending on phenotype.

MRI is often normal or non-specific and does not establish the diagnosis.

Sodium-channel blockers

International expert consensus supports sodium-channel blockers as preferred treatment for gain-of-function SCN8A focal epilepsy phenotypes, including severe and mild-to-moderate DEE and self-limited infantile epilepsy.

Examples used clinically include phenytoin, carbamazepine, oxcarbazepine, lacosamide, lamotrigine and rufinamide, depending on the individual situation.

Loss-of-function treatment differs

For neurodevelopmental disorder with generalised epilepsy caused by loss-of-function variants, sodium-channel blockers may be relatively unsuitable.

Consensus favours medicines used for generalised epilepsies such as valproate, ethosuximide or lamotrigine depending on seizure type.

Levetiracetam nuance

The global SCN8A consensus considered levetiracetam relatively contraindicated in gain-of-function phenotypes because worsening has been reported in some individuals.

This does not mean every person will worsen, but it illustrates why mechanism-specific interpretation matters.

SUDEP

SCN8A-DEE is associated with increased mortality, including SUDEP.

Standard SUDEP counselling, optimisation of convulsive seizure control and individual night-time safety planning are important.

Movement and autonomic features

Ataxia, dystonia, hypotonia, gastrointestinal problems and cortical visual impairment can occur in severe phenotypes.

Care should address the whole neurological disorder rather than seizures alone.

Inheritance

Severe gain-of-function DEE variants are often de novo. Milder self-limited infantile epilepsy may be inherited.

Genetic counselling is needed because recurrence risk depends on whether the variant is de novo, inherited or present as parental mosaicism.

Precision therapies

SCN8A is an active precision-medicine research target. Future therapies aim to reduce excessive Nav1.6 activity in gain-of-function disease or restore function where appropriate.

These approaches remain investigational.

Worldwide access

The 2024 global consensus was specifically developed to reduce international variation in recognition and treatment.

However, access to functional variant interpretation and specialist epilepsy genetics remains unequal.

The central point

SCN8A treatment depends heavily on mechanism. Gain-of-function and loss-of-function phenotypes should not be managed as though they are biologically identical.

Sources

Medical note: treatment should be based on variant mechanism, seizure phenotype and specialist assessment.

Evidence checked: September 2026.